Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) Stock Information | RedChip

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)


$2.7900
-0.2000 ( -7.31% ) 898.9K

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.

Market Data


Open


$2.7900

Previous close


$2.9900

Volume


898.9K

Market cap


$199.19M

Day range


$2.7550 - $3.0160

52 week range


$2.6600 - $18.0700

SEC Filings


Form Type Description Pages Date
8-k 8K-related 69 Apr 09, 2024
8-k 8K-related 17 Feb 27, 2024
10-k Annual reports 228 Feb 27, 2024
8-k 8K-related 16 Feb 15, 2024
4 Insider transactions 1 Feb 12, 2024
4 Insider transactions 1 Feb 12, 2024
4 Insider transactions 1 Feb 05, 2024
4 Insider transactions 1 Feb 05, 2024
4 Insider transactions 1 Feb 05, 2024
4 Insider transactions 1 Feb 05, 2024

Latest News